Methylphenidate improves prefrontal cortical cognitive function through α2 adrenoceptor and dopamine D1 receptor actions: Relevance to therapeutic effects in Attention Deficit Hyperactivity Disorder

Behavioral and Brain Functions

Volumn 1, Issue , 2005, Pages

  Arnsten, Amy F T ^a   Dudley, Anne G ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ALPHA 2 ADRENERGIC RECEPTOR; CATECHOLAMINE; DOPAMINE 1 RECEPTOR; IDAZOXAN; METHYLPHENIDATE;

ANALYTICAL ERROR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATTENTION DEFICIT DISORDER; BRAIN REGION; COGNITION; CONTROLLED STUDY; DISEASE MODEL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; INHIBITION KINETICS; MALE; NONHUMAN; OUTCOME ASSESSMENT; PERSEVERATION; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; RECEPTOR UPREGULATION; TASK PERFORMANCE; TREATMENT OUTCOME;

EID: 27744605990     PISSN: 17449081     EISSN: None     Source Type: Journal    
DOI: 10.1186/1744-9081-1-2     Document Type: Article

References (67)

1. Arnsten AFT, Castellanos FX: Neurobiology of attention regulation and its disorders. In Textbook of Child and Adolescent Psychopharmacology Edited by: Martin A, Scahill L, Charney D and Leckman J. NY, Oxford Univ. Press; 2002:99-109.
2. Goldman-Rakic PS: The prefrontal landscape: implications of functional architecture for understanding human mentation and the central executive. Phil Trans R Soc London 1996, 351:1445-1453.
3. Robbins TW: Dissociating executive functions of the prefrontal cortex. Phil Trans R Soc London 1996, 351:1463-1471.
4. Stuss DT, Knight RT: Principles of Frontal Lobe Function. New York, Oxford University Press; 2002:616.
5. Barkley RA, Grodzinsky G, DuPaul GJ: Frontal lobe functions in Attention Deficit Disorder with and without Hyperactivity: A review and research report. J Abnormal Child Psych 1992, 20:163-188.
6. Vaidya CJ, Austin G, Kirkorian G, Ridlehuber HW, Desmond JE, Glover GH, Gabrieli JDE: Selective effects of methylphenidate in attention deficit hyperactivity disorder: A functional magnetic resonance study. Proc Nat Acad Sci USA 1998, 95:14494-14499.
7. Mehta AD, Ulbert I, Schroeder CE: Intermodal selective attention in monkeys. I: distribution and timing of effects across visual areas. Cerebral Cortex 2000, 10:343-358.
8. Solanto MV: Dopamine dysfunction in AD/HD: integrating clinical and basic neuroscience research. Behav Brain Res 2002, 130:65-71.
9. Volkow ND, Fowler JS, Wang GJ, Ding YS, Gatley SJ: Role of dopamine in the therapeutic and reinforcing effects of methylphenidate in humans: results from imaging studies. Eur Neuropsychopharmacol 2002, 12:557-566.
10. Ernst M, Zametkin AJ, Matochik JA, Jons PH, Cohen RM: DOPA decarboxylase activity in attention deficit disorder adults. A [fluorine-18]fluorodopa positron emission tomographic study. J Neurosci 1998, 18:5901-5907.
11. Kuczenski R, Segal DS: Exposure of adolescent rats to oral methylphenidate: preferential effects on extracellular norepinephrine and absence of sensitization and cross-sensitization to methamphetamine. J Neurosci 2002, 22:7264-7271.
12. Gerasimov MR, Franceschi M, Volkow ND, Gifford A, Gatley SJ, Marsteller D, Molina PE, Dewey SL: Comparison between intraperitoneal and oral methyiphenidate administration: A microdialysis and locomotor activity study. J Pharmacol Exp Ther 2000, 295:51-57.
13. Gaytan O, Ghelani D, Martin S, Swann AC, Dafny N: Methylphenidate: diurnal effects on locomotor and stereotypic behavior in the rat. Brain Res 1997, 777:1-12.
14. McDougall SA, Collins RL, Karper PE, Watson JB, Crawford CA: Effects of repeated methylphenidate treatment in the young rat: sensitization of both locomotor activity and stereotyped sniffing. Exp Clin Psychopharmacol 1999, 7:208-218.
15. Sproson EJ, Chantrey J, Hollis C, Marsden CA, Fone KC: Effect of repeated methylphenidate administration on presynaptic dopamine and behaviour in young adult rats. J Psychopharmacol 2001, 15:67-75.
16. Wultz B, Sagvolden T, Moser EI, Moser MB: The spontaneously hypertensive rat as an animal model of attention-deficit hyperactivity disorder: effects of methylphenidate on exploratory behavior. Behav Neural Biol 1990, 53:88-102.
17. Amini B, Yang PB, Swann AC, Dafny N: Differential locomotor responses in male rats from three strains to acute methylphenidate. Int J Neurosci 2004, 114:1063-1084.
18. Kuczenski R, Segal DS: Locomotor effects of acute and repeated threshold doses of amphetamine and methylphenidate: relative roles of dopamine and norepinephrine. J Pharmacol Exp Ther 2001, 296:876-883.
19. Berridge CW, Stalnaker TA: Relationship between low-dose amphetamine-induced arousal and extracellular norepinephrine and dopamine levels within prefrontal cortex. Synapse 2002, 46:140-149.
20. Arnsten AFT, Robbins TW: Neurochemical modulation of prefrontal cortical function in humans and animals. In Principles of Frontal Lobe Function Edited by: Stuss DT and Knight RT. New York, Oxford University Press; 2002:51-84.
21. Arnsten AFT, Li BM: Neurobiology of executive functions: Catecholamine influences on prefrontal cortical function. Biological Psychiatry 2005, in press:.
22. Arnsten AFT: Stress impairs PFC function in rats and monkeys: Role of dopamine D1 and norepinephrine alpha-1 receptor mechanisms. Prog Brain Res 2000, 126:183-192.
23. Larsen JK, Divac I: Selective ablations within the prefrontal cortex of the rat and performance of delayed alternation. Physialog Psychol 1978, 6:15-17.
24. Mishkin M: Perseveration of central sets after frontal lesions in monkeys. In The Frontal Granular Cortex and Behavior Edited by: Warren JM and Akert K. New York, McGraw-Hill; 1964:219-241.
25. Butter CM: Perseveration in extinction and in discrimination reversal following selective frontal ablations in Macaca mulatta. Physiol Behav 1968, 4:163-171.
26. Collins P, Roberts AC, Dias R, Everitt BJ, Robbins TW: Perseveration and strategy in a novel spatial self-ordered sequencing task for nonhuman primates: effects of excitotoxic lesions and dopamine depletions of the prefrontal cortex. J Cognitive Neuroscience 1998, 10:332-354.
27. Zahrt J, Taylor JR, Mathew RG, Arnsten AFT: Supranormal stimulation of dopamine D1 receptors in the rodent prefrontal cortex impairs spatial working memory performance. J Neurosci 1997, 17:8528-8535.
28. Arnsten AFT, Mathew R, Ubriani R, Taylor JR, Li BM: Alpha-1 noradrenergic receptor stimulation impairs prefrontal cortical cognitive function. Biol Psychiatry 1999, 45:26-31.
29. Birnbaum SG, Gobeske KT, Auerbach J, Taylor JR, Arnsten AFT: A role for norepinephrine in stress-induced cognitive deficits: Alpha-I-adrenoceptor mediation in prefrontal cortex. Biol Psychiatry 1999, 46:1266-1274.
30. Elliott R, Sahakian BJ, Matthews K, Bannerjea A, Rimmer J, Robbins TW: Effects of methylphenidate on spatial working memory and planning in healthy young adults. Psychopharmacology 1997, 131:196-206.
31. Trommer BL, Hoeppner JA, Zecker SG: The go-no go test in attention deficit disorder is sensitive to methylphenidate. J Child Neurol 1991, 6 Suppl:S128-31.
32. Bedard AC, Ickowicz A, Logan GD, Hogg-Johnson S, Schachar R, Tannock R: Selective inhibition in children with attention-deficit hyperactivity disorder off and on stimulant medication. J Abnorm Child Psychol 2003, 31:315-327.
33. Aron AR, Dowson JH, Sahakian BJ, Robbins TW: Methylphenidate improves response inhibition in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 2003, 54:1465-1468.
34. Mehta MA, Goodyer IM, Sahakian BJ: Methylphenidate improves working memory and set-shifting in AD/HD: relationships to baseline memory capacity. J Child Psychol Psychiatry 2004, 45:293-305.
35. Turner DC, Blackwell AD, Dowson JH, McLean A, Sahakian BJ: Neurocognitive effects of methylphenidate in adult attention-deficit/ hyperactivity disorder. Psychopharmacology 2004, epub:.
36. Mehta MA, Owen AM, Sahakian BJ, Mavaddat N, Pickard JD, Robbins TW: Methylphenidate enhances working memory by modulating discrete frontal and parietal lobe regions in the human brain. J Neuroscience 2000, 20:RC651-656.
37. Robbins TW, Sahakian BJ: "Paradoxical" effects of psychomotor stimulant drugs in hyperactive children from the standpoint of behavioral pharmacology. Neuropharmacol 1979, 18:931-950.
38. Solanto MV, Wender EH: Does methylphenidate constrict cognitive functioning? J Am Acad Child Adolesc Psychiatry 1989, 28:897-902.
39. Dyme IZ, Sahakian BJ, Golinko BE, Rabe EF: Perseveration induced by methylphenidate in children: preliminary findings. Prog Neuropsychopharmacol Biol Psychiatry 1982, 6:269-273.
40. Tannock R, Schachar R: Methylphenidate and cognitive perseveration in hyperactive children. J Child Psychol Psychiatry 1992, 33:1217-1228.
41. Douglas VI, Barr RG, Desilets J, Sherman E: Do high doses of stimulants impair flexible thinking in attention-deficit hyperactivity disorder? J Am Acad Child Adolesc Psychiatry 1995, 34:877-885.
42. Bymaster FP, Katner JS, Nelson DL, Hemrick-Luecke SK, Threlkeld PG, Heiligenstein JH, Morin SM, Gehlert DR, Perry KW: Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/ hyperactivity disorder. Neuropsychopharmacology 2002, 27:699-711.
43. Brozoski T, Brown RM, Rosvold HE, Goldman PS: Cognitive deficit caused by regional depletion of dopamine in prefrontal cortex of rhesus monkey. Science 1979, 205:929-931.
44. Sawaguchi T, Goldman-Rakic PS: The role of D1-dopamine receptors in working memory: local injections of dopamine antagonists into the prefrontal cortex of rhesus monkeys performing an oculomotor delayed response task. J Neurophysiol 1994, 71:515-528.
45. Sawaguchi T, Goldman-Rakic PS: D1 dopamine receptors in prefrontal cortex: Involvement in working memory. Science 1991, 251:947-950.
46. Granon S, Passetti F, Thomas KL, Dalley JW, Everitt BJ, Robbins TW: Enhanced and impaired attentional performance after infusion of D1 dopaminergic receptor agents into rat prefrontal cortex. J Neurosci 2000, 20:1208-1215.
47. Biederman J, Spencer T: Attention-deficit/hyperactivity disorder (ADHD) as a noradrenergic disorder. Biol Psychiatry 1999, 46:1234-1242.
48. Biederman J, Spencer TJ: Genetics of childhood disorders: XIX. ADHD, Part 3: Is ADHD a noradrenergic disorder? J Am Acad Child Adolesc Psychiatry 2000, 39:1330-1333.
49. Viggiano D, Vallone D, Sadile A: Dysfunctions in dopamine systems and ADHD: evidence from animals and modeling. Neural Plast 2004, 11:97-114.
50. Kuczenski R, Segal DS: Effects of methylphenidate on extracellular dopamine, serotonin, and norepinephrine: Comparison with amphetamine. J Neurochem 1997, 68:2032-2037.
51. Ma CL, Arnsten AFT, Li BM: Locomotor hyperactivity induced by blockade of prefrontal cortical alpha-2-adrenoceptors in monkeys. Biological Psychiatry 2005, in press:.
52. Ma CL, Qi XL, Peng JY, Li BM: Selective deficit in no-go performance induced by blockade of prefrontal cortical alpha2-adrenoceptors in monkeys. Neuroreport 2003, 14:1013-1016.
53. Li BM, Mei ZT: Delayed response deficit induced by local injection of the alpha-2 adrenergic antagonist yohimbine into the dorsolateral prefrontal cortex in young adult monkeys. Behav Neurol Biol 1994, 62:134-139.
54. Li BM, Mao ZM, Wang M, Mei ZT: Alpha-2 adrenergic modulation of prefrontal cortical neuronal activity related to spatial working memory in monkeys. Neuropsychopharmacol 1999, 21:601-610.
55. Arnsten AFT, Cai JX, Goldman-Rakic PS: The alpha-2 adrenergic agonist guanfacine improves memory in aged monkeys without sedative or hypotensive side effects. J Neurosci 1988, 8:4287-4298.
56. Mao ZM, Arnsten AFT, Li BM: Local infusion of alpha-1 adrenergic agonist into the prefrontal cortex impairs spatial working memory performance in monkeys. Biol Psychiatry 1999, 46:1259-1265.
57. Arnsten AFT, Contant TA: Alpha-2 adrenergic agonists decrease distractability in aged monkeys performing a delayed response task. Psychopharmacology 1992, 108:159-169.
58. Steere JC, Arnsten AFT: The alpha-2A noradrenergic agonist, guanfacine, improves visual object discrimination reversal performance in rhesus monkeys. Behav Neurosci 1997, 111:1-9.
59. Wang M, Ji JZ, Li BM: The alpha(2A)-adrenergic agonist guanfacine improves visuomotor associative learning in monkeys. Neuropsychopharmacology 2004, 29:86-92.
60. Wang M, Tang ZX, Li BM: Enhanced visuomotor associative learning following stimulation of alpha 2A-adrenoceptors in the ventral prefrontal cortex in monkeys. Brain Res 2004, 1024:176-182.
61. Avery RA, Franowicz JS, Studholme C, van Dyck CH, Arnsten AFT: The alpha-2A-adenoceptor agonist, guanfacine, increases regional cerebral blood flow in dorsolateral prefrontal cortex of monkeys performing a spatial working memory task. Neuropsychopharmacology 2000, 23:240-249.
62. Spencer T, Heiligenstein JH, Biederman J, Faries DF, Kratochvil CJ, Conners CK, Potter WZ: Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2002, 63:1140-1147.
63. Scahill L, Chappell PB, Kim YS, Schultz RT, Katsovich L, Shepherd E, Arnsten AFT, Cohen DJ, Leckman JF: Guanfacine in the treatment of children with tic disorders and ADHD: A placebo-controlled study. Amer J Psychiatry 2001, 158:1067-1074.
64. Franowicz JS, Kessler L, Dailey-Borja CM, Kobilka BK, Limbird LE, Arnsten AFT: Mutation of the alpha2A-adrenoceptor impairs working memory performance and annuls cognitive enhancement by guanfacine. J Neurosci 2002, 22:8771-8777.
65. Tanila H, Rama P, Carlson S: The effects of prefrontal intracortical microinjections of an alpha-2 agonist, alpha-2 antagonist and lidocaine on the delayed alternation performance of aged rats. Brain Res Bull 1996, 40:117-119.
66. Rama P, Linnankoski I, Tanila H, Pertovaara A, Carlson S: Medetomidine, atipamezole, and guanfacine in delayed response performance of aged monkeys. Pharmacol Biochem Behav 1996, 54:1-7.
67. Jakala P, Riekkinen M, Sirvio J, Koivisto E, Kejonen K, Vanhanen M, Riekkinen PJ: Guanfacine, but not clonidine, improves planning and working memory performance in humans. Neuropsychopharmacology 1999, 20:460-470.